Most of the patients who relapsed after stopping the drug took timely retreatment treatment, and the practice proved that the antiviral treatment again is safe and effective, and the disease can be controlled stably for a long time with a high quality of life. A small number of patients have been tried and observed on the basis of respecting their wishes. A very small percentage of patients did develop HBVDNA positivity after regulated drug discontinuation, but liver function has been normal and there is no sign of disease progression on relevant imaging and other tests. Patients were unwilling to take oral antiviral drugs again, and these patients were treated with close follow-up. A small proportion of patients took interferon therapy after relapse from the drug, most of them had poor efficacy, and satisfactory results were achieved after switching to oral nucleoside (acid) analogues. Therefore, the suitability of interferon therapy after relapse on oral antivirals needs to be answered by more evidence-based medical data. A subset of young patients with ALT rising above 1000u/L after relapse on discontinued drugs are treated without antivirals and with intensive hepatoprotective support under close observation. Due to their own intense immune clearance, their HBVDNA load decreased from one hundred to one thousand times after one month, but in the subsequent observation, most of them showed virological rebound and recurrent abnormal liver function. This shows that it is difficult to rely on the patient’s own immune clearance to achieve durable control of HBVDNA replication after drug discontinuation relapse. A small proportion of patients show spontaneous e antigen seroconversion, but show significant manifestations of liver fibrosis. There is a lack of systematic evidence-based medical research and evaluation of relapse retreatment after drug discontinuation, and the relapse rate after discontinuation of oral antiviral drugs is high, so there is an urgent need to develop guidelines for relapse retreatment and to explore retreatment options for relapse after discontinuation of various antiviral drugs. The issues of drug selection, duration of therapy and management of incomplete response during post-relapse retreatment are difficult issues in post-relapse retreatment and need to be clarified by more evidence-based medical evidence. With such a rich resource pool of hepatitis B, Chinese infectious physicians should produce more original and worthy research results in post-relapse relapse treatment!